SCHEMBL14917449

SCHEMBL14917449

NC(=O)c1c(-c2cccnc2)ncc(F)c1N

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 8/20 0.47
MKNK2 Q9HBH9 7/20 0.47
LIMK1 P53667 1/20 0.44
IKBKB O14920 1/20 0.43
CHEK2 O96017 1/20 0.42
F7 P08709 1/20 0.41
F3 P13726 1/20 0.41
SARM1 Q6SZW1 1/20 0.41
SIRT2 Q8IXJ6 1/20 0.41
SIRT6 Q8N6T7 1/20 0.41
SIRT1 Q96EB6 1/20 0.41
SIRT3 Q9NTG7 1/20 0.41
SIRT5 Q9NXA8 1/20 0.41
SIRT4 Q9Y6E7 1/20 0.41
CYP2C19 P33261 3/20 0.41
ADORA2B P29275 2/20 0.41
CYP3A4 P08684 2/20 0.41
ATR Q13535 1/20 0.40
HSP90AA1 P07900 1/20 0.40
HSP90AB1 P08238 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14917472 0.85 CDC7 (0.45) MKNK1LIMK1CHEK2ATRHSP90AA1
SCHEMBL14917433 0.78 MKNK1 (0.50) MKNK1MKNK2LIMK1IKBKBCHEK2
SCHEMBL14917451 0.78 CHEK2 (0.48) MKNK1MKNK2IKBKBCHEK2F7
SCHEMBL6315391 0.71 IKBKB (0.51) MKNK1MKNK2LIMK1IKBKBCHEK2
SCHEMBL14917452 0.71 MKNK1 (0.52) MKNK1MKNK2IKBKBCHEK2CYP2C19
SCHEMBL14917436 0.71 CHEK2 (0.52) MKNK1MKNK2LIMK1IKBKBCHEK2
SCHEMBL1571384 0.70 MKNK1 (0.55) MKNK1MKNK2F7F3SARM1
SCHEMBL2228105 0.70 MKNK1 (0.54) MKNK1MKNK2IKBKBCHEK2F7
SCHEMBL29575496 0.70 MKNK1 (0.55) MKNK1MKNK2F7F3SARM1
SCHEMBL30665107 0.70 MKNK1 (0.54) MKNK1MKNK2IKBKBCHEK2F7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130116430-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2013-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116430-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF SYK, CD38, BTK MKNK1 2094/4885MKNK2 1846/4885LIMK1 2433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.